Indolent lymphoma at ASH 2014: new kids on the block (iDrugs)

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology support the potential use of chemotherapy-free combinations in first-line treatment of follicular lymphoma. Rituximab maintenance seems to be very useful after autologous stem cell transplantation in younger patients with mantle cell lymphoma (MCL). In elderly MCL patients the integration of bortezomib in frontline treatment strategies is very promising. Moreover, new therapeutic agents such as ibrutinib and idelalisib are tested successfully in clinical trials in relapsed indolent lymphoma.